nSMase3: Novel neutral Sphingomyelinase and its use for diagnostics andtherapy with focus on heart muscle diseases and male fert
A novel human TNF-responsible neutral phingomyelinase enzyme (nSMase3) has been identified. Furthermore, the invention relates to the use of nSMase3 as pharmaceutical and diagnostic target
and to appropriate test systems. The human enzyme was identified by screening database sequences with up to now unknow n function w ith a short sequence derived from a bovine neutral sphingomyelinase. The identified nSMase3 shows no significant homologies to the well-know n human neutral sphingomyelinases type 1 and type 2.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Breaking the Ice: Glacier Melting Alters Arctic Fjord Ecosystems
The regions of the Arctic are particularly vulnerable to climate change. However, there is a lack of comprehensive scientific information about the environmental changes there. Researchers from the Helmholtz Center…
Global Genetic Insights into Depression Across Ethnicities
New genetic risk factors for depression have been identified across all major global populations for the first time, allowing scientists to predict risk of depression regardless of ethnicity. The world’s…
Back to Basics: Healthy Lifestyle Reduces Chronic Back Pain
Low back pain is a leading cause of disability worldwide with many treatments, such as medication, often failing to provide lasting relief. Researchers from the University of Sydney’s Centre for Rural…